Novel therapy for children with chronic hormone deficiency provides lifeline for parents
- Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
- Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
- This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.
Recent Blog Posts
A message from 'Same but Different': ‘Journey of Hope’ is a short film offering a glimpse in to the lives of families where children have received a rare genomic diagnosis. In a world where labels and diagnosis are often framed negatively, this film highlights the...
The Society for Endocrinology, the Association of Anaesthetists and the Royal College of Physicians have published new "Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency." You can access the...
You can now send donations to us using bank transfer through JustGiving. No setup is necessary and the process using bank-grade security. Read more at JustGiving. Recent Blog Posts